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INTRODUCTION
Parkinson’s disease (PD) is a common neurodegen-
erative disorder affecting approximately 1% of the 
population over 60 years of age1. The core neuro-
pathological features of PD are the loss of dopaminer-
gic neurons in the substantia nigra and the deposition 
of specific cytoplasmic protein aggregates, known as 
Lewy bodies. Approximately 90-95% of PD patients 
have sporadic disease attributed to interactions be-
tween environmental conditions and the genetic con-
stitution of each individual, whereas 5-10% of PD 
cases have a positive familial background with five 
genes: a-synuclein, parkin, PTEN induced putative 
kinase 1, DJ-1 and Leucine-rich repeat kinase 2 being 
definitely associated with the Mendelian inheritance 
of the disease2,3.
Neurotrophic factors are small secreted proteins 
which regulate neuronal survival, growth, differen-
tiation and migration in the nervous system. Neuro-
trophic factors belong to three main protein families: 
neurotrophins, neuropoietic cytokines and glial cell 
line-derived neurotrophic factor family4. Recently, a 
novel family of neurotrophic factors has been discov-
ered, consisting of mesencephalic astrocyte-derived 
neurotrophic factor5 and cerebral dopamine neuro-
trophic factor (CDNF)6. Neurotrophic factors are 
considered as promising factors for the treatment of 
a variety of neurological diseases including Alzheim-
er’s disease, PD, Huntington’s disease, epilepsy and 
neuropathies7. In the present study, in an attempt to 
investigate the role of genetic variations in CDNF in 
PD pathogenesis, we examined for the first time the 
possible association of the CDNF rs11259365 poly-
morphism with PD, in the Greek population.
PATIENTS AND METHODS
In the present study, we examined 53 unrelated in-
dividuals diagnosed for PD8 without positive family 
history. The control group consisted of 52 healthy in-
dividuals. All participants gave informed consent for 
this study. Genomic DNA was extracted in all subjects 
from peripheral blood leukocytes according to stan-
dard procedures. The CDNF genotypes were deter-
mined using a polymerase chain reaction-restriction 
fragment length polymorphism method. The target 
region of CDNF was amplified with the following 
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set of primers: forward 5’-AAAGAAACCCCCAG-
TATTCC-3’; reverse 5’- ATATGGTAGGCGCT-
CAGTTT-3’. The PCR conditions used for the rs 
11259365 polymorphism were: initial denaturation at 
94°C for 5 minutes followed by 25 cycles of 94°C for 
30 seconds, 60 to 50°C touchdown annealing for 30 
seconds at 0.5°C per cycle, and 72°C for 45 seconds, 
with a final extension at 72°C for 10 minutes. Diges-
tion with Sau3ΑΙ restriction enzyme (New England 
Biolabs) at 37oC yields 146+89 bp bands for the G 
allele and 111+89+35 bp bands for the C allele, re-
spectively. Digestion products were resolved on a 4% 
agarose gel, stained in ethidium bromide solution and 
visualized with an ultraviolet light.
RESULTS
In our cohort the distribution of genotype frequen-
cies was GG = 90.6%, GC = 7.5%, CC = 1.9%; and 
GG = 92.3%, GC = 7.7%, CC = 0.0% for the PD and 
control group, respectively (p = 0.607). Allele frequen-
cies were G= 93.34%, C = 5.66% and G = 96.15%, 
C = 3.85% for patients and controls, respectively 
(p = 0.538) (Table 1).
DISCUSSION
CDNF is a newly identified neurotrophic factor with 
neurotrophic, neuroprotective and neurorestorative 
activities. In vivo studies, have shown CDNF to exert 
a neurotrophic effect as well as to protect and repair 
dopaminergic neurons6. Interestingly, injecting CDNF 
before 6-hydroxydopamine into the striatum in a rat 
model, significantly reduced amphetamine-induced 
ipsilateral turning behaviour and almost completely 
rescued dopaminergic tyrosine hydroxylase-positive 
cells in the substantia nigra. When CDNF was inject-
ed into the striatum four weeks after the lesion, sig-
nificant recovery of motor function was noticed after 
eight weeks, supporting the neurorestorative role of 
CDNF6. 
CDNF is located on chromosome 10p13. CDNF 
contains 4 exons and spans 18,732bp. The rs11259365 
polymorphism is located on intron 1 of CDNF. Af-
ter the discovery of CDNF as a member of a new 
neurotrophic family, the genetic role of variations in 
CDNF was firstly examined in cocaine dependence, 
as cocaine induced neuroplasticity changes in the 
mesocorticolimbic dopamine systems are thought 
to be implicated in the pathophysiology of this be-
haviour. However, negative results were found for 
this association9. We examined the possible associa-
tion of the intronic rs11259365 polymorphism with 
PD in the Greek population. An intronic SNP may 
act as a susceptibility factor for a disease if it is in 
linkage disequilibrium with other functional SNPs in 
exonic regions or it can directly affect gene expres-
sion. In our study no association was found between 
the rs11259365 polymorphism and PD, in the Greek 
population. These preliminary results provide a strong 
indication that this polymorphism does not have a ma-
jor role in PD pathogenesis. In the study of Choi et 
al, only the C allele of the rs7094179 CDNF intronic 
polymorphism was found to be a possible suscepti-
bility allele for PD, in the Korean population10. Addi-
tional studies with larger sample size and in different 
populations are needed to further investigate the pos-
sible role of genetic variations in CDNF in PD.
Abbreviations
PD: Parkinson’s disease
CDNF: cerebral dopamine neurotrophic factor
Table 1. CDNF genotype and allele distributions (%).
Genotypes n % Alleles %
CDNF rs11259365 polymorphism G/G G/C C/C G C
PD (N = 53)
48
(90.6)
4
(7.5)
1
(1.9)
100 (94.34)
6
(5.66)
CONTROLS (N = 52)
48
(92.3)
4
(7.7)
0 
(0.0)
100
(96.15)
4
(3.85)
X2 P = 0.607
(OR = 0.8, 95% CI:0.20-3.15)
P = 0,538
(OR = 0.67, 95% CI:0.19-2.39)
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ΠΕΡΙΛΗΨΗ: Ο εγκεφαλικός νευροτροφικός παράγοντας ντοπαμίνης (CDNF) είναι ένας νεοανακαλυφθείς νευροτροφικός 
παράγοντας. Στην παρούσα μελέτη εξετάστηκε ο πολυμορφισμός CDNF rs11259365 σε 53 Έλληνες ασθενείς με σποραδική 
νόσο Πάρκινσον (ΝΠ) και 52 υγιή άτομα, με τη μέθοδο PCR-RFLP. Δε βρέθηκε κάποια συσχέτιση μεταξύ του συγκεκριμένου 
πολυμορφισμού και της ΝΠ, στον Ελληνικό πληθυσμό.
Λέξεις Κλειδιά: Νόσος Πάρκινσον, Γονίδιο, CDNF, Πολυμορφισμός.
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